Warner Chilcott Plc (WCRX): Can Earnings Heal Its Woes?

Page 2 of 2

Warner Chilcott may even turn the tables and decide to be an acquirer. Rumors that the company might be involved in a potential bid for Endo Health Solutions Inc (NASDAQ:ENDP) back in February haven’t panned out, but an acquisition could help the company bolster its pipeline. At the same time, though, its current debt load could make a buyout difficult from a financial perspective.

Still, Warner Chilcott has seen good news on the development front. Its Doryx delayed-release oral antibiotic got Food and Drug Administration approval in its 200 mg form, with Warner Chilcott expecting to launch the drug in July. Just earlier today, the company had a new oral contraceptive approved by the FDA for an expected August launch.

In Warner Chilcott Plc (NASDAQ:WCRX)’s earnings, look for the company to discuss its overall strategic plan going forward. With the drugmaker having apparently survived the worst of its tumultuous recent past, investors should hope that Warner Chilcott can make progress on getting its debt levels down and keep its drug pipeline flowing.

The article Can Warner Chilcott Start Growing Again? originally appeared on Fool.com and is written by Dan Caplinger.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool recommends Procter & Gamble.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2